Late-stage blow to AstraZeneca’s prostate cancer drug
February 7, 2011Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan
A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Survey shows doctors support FDA Avastin decision
February 7, 2011Sales and Marketing FDA, Roche, Sermo, avastin, bevacizumab
A survey of US doctors suggests that a majority support the FDA’s decision to take away Avastin’s licence for use …
GSK profits slump amid ongoing Avandia woes
February 7, 2011Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline
GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …
Merck dipped into the red as 2010 ended
February 4, 2011Sales and Marketing 2010 pharma results, Merck & Co
Merck & Co made a $531 million loss in the final quarter of 2010 – down from a profit of …
Digital Pharma: Merck Serono launches campaign for cancer carers
February 4, 2011Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer
Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …
Bayer’s regorafenib gains orphan status for GIST
February 4, 2011Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib
Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …
Sparkling celebrations at PM Awards’ silver jubilee
February 4, 2011Medical Communications Langland, PM Society Advertising Awards, advertising, awards, pm society
The PM Society marked the 25th anniversary of its annual advertising awards with a ceremony that glittered almost as much …
Bayer and Zydus Cadila sign India deal
February 4, 2011Sales and Marketing Bayer, India, Indian pharmaceutical industry, Zydus Cadila
Bayer HealthCare and the Indian company Zydus Cadila have signed a deal to form a new joint venture. A new …
ABPI backs UK science after Pfizer’s R&D exit
February 4, 2011Research and Development Kent, Pfizer, Sandwich
The ABPI has defended the UK’s research environment against mounting criticism following Pfizer’s decision to close its Kent research base. …
LEC appoints joint creative directors
February 4, 2011Medical Communications Harry Armfield, Kim Hughes, LEC, Lane Earl Cox, appointment, medical communications
Lane Earl Cox has promoted Harry Armfield and Kim Hughes to the position of joint creative directors. Harry and Kim …
Working Life: Merck Sharp & Dohme medical director Paul Robinson
February 4, 2011Business Services, Research and Development MSD, Paul Robinson, Working Life, careers, merck sharp and dohme, recruitment
Paul Robinson, medical director at Merck Sharp & Dohme, looks at how his field is changing, the most enjoyable things …
Pressure mounts on Servier over Mediator controversy
February 3, 2011Sales and Marketing France, G5, Mediator, Servier, benfluorex
Dr Jacques Servier has stepped down from his role as head of a French pharma industry association as controversy grows …
Five capabilities of centered leadership
February 3, 2011Manufacturing and Production, Research and Development, Sales and Marketing Caroline Webb, Joanna Barsh, Josephine Mogelof, McKinsey & Company, leadership
The business environment has become more demanding: the global financial crisis and subsequent economic downturn have ratcheted up the pressure …
Pfizer appoints Dr Yvonne Greenstreet to specialty care business
February 3, 2011Research and Development Dr Yvonne Greenstreet, Pfizer, appointment, specialty care
Dr Yvonne Greenstreet has joined Pfizer to head up medicines development for its Specialty Care business unit. She moves to …
Roche weathers tough year and looks to pipeline for 2011
February 3, 2011Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab
Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
Jango to manage Grünenthal pain awards
February 3, 2011Medical Communications Grunenthal, Jango, awards, disease awareness campaigns
Jango Communications has been appointed by Grünenthal to manage the Pain Awards Programme they are sponsoring this year. German-based Grünenthal, …
The Project Management Office – Accelerating Project Management Maturity
February 3, 2011Sales and Marketing Kinapse, White paper
Success in the life sciences industry depends on allocation of scarce resource to the right projects at different stages of …
Diabetes success for Sanofi, disappointment for Roche
February 2, 2011Roche, Sanofi, diabetes
The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …
Government seeks to salvage Pfizer site
February 2, 2011Research and Development Pfizer, Sandwich
Science minister David Willetts says the government will do all it can to maintain pharma research in Kent, after Pfizer …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
